[Rifaximin improves clinical symptoms and short-term survival in cirrhotic patients with refractory type ascites].

Wang, Z; Hou, W; Zhang, W; Wu, H X; Zheng, S J; Hu, Z J

Wang, Z; Hou, W; Zhang, W; Wu, H X; Zheng, S J; Hu, Z J.

Afiliación

Wang Z; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Hou W; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zhang W; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Wu HX; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zheng SJ; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Hu ZJ; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Zhonghua Gan Zang Bing Za Zhi ; 30(11): 1170-1174, 2022 Nov 20.

Article en Zh | MEDLINE | ID: mdl-36891693

Asunto(s)

Encefalopatía Hepática; Rifamicinas; Humanos; Rifaximina/uso terapéutico; Rifamicinas/uso terapéutico; Ascitis/etiología; Estudios Retrospectivos; Cirrosis Hepática/tratamiento farmacológico; Encefalopatía Hepática/complicaciones; Resultado del Tratamiento; Peso Corporal

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rifamicinas / Encefalopatía Hepática Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Zhonghua Gan Zang Bing Za Zhi Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google